atherosclerosis | GenomeWeb

atherosclerosis

The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.

The researchers will use TwoXar's software to predict potential candidates for atherosclerosis drugs and test them in pre-clinical studies.

The company's pipeline consists of tests for early detection of Alzheimer's and atherosclerosis as well as for guiding statin therapy.

Interleukin will provide its genetic tests for inflammatory and metabolic diseases for a study directed at a cardiovascular disease drug in development.

NEW YORK (GenomeWeb) – Cofactor Genomics said on Thursday it has won a contract from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute to identify sites of epigenetic modifications that contribute to cardiovascular disease endpoints.

NEW YORK (GenomeWeb) – New data published this month by researchers from Regulus Therapeutics and academic collaborators show that long-term therapeutic silencing of microRNA-33 could result in a number of deleterious effects in mice including fatty liver and elevated triglyceride levels.

NEW YORK (GenomeWeb News) – Global Genomics Group and Quintiles announced today a collaboration aimed at developing new diagnostic tools and treatments for cardiovascular diseases as part of the Genetic Loci and Burden of Atherosclerotic Lesions (GLOBAL) clinical study.

A team led by Emory University researchers this week published new data showing that a specific microRNA plays a key role in the development of atherosclerosis in a mouse model of the disease, and that inhibiting its human homolog may have therapeutic potential.

NEW YORK (GenomeWeb News) – Illumina said today that it will partner with Global Genomics Group (G3) to provide whole-genome sequencing for the Genetic Loci and the Burden of Atherosclerotic Lesions, or GLOBAL, clinical trial.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.